Myelofibrosis market

View All

momelotinib-for-myelofibrosis-treatment
Myelofibrosis Treatment Market Heats Up with GSK’s Momelotinib Entry

On September 15, the FDA authorized GSK’s oral medication momelotinib, now known as Ojjaara, for the treatment of myelofibrosis in adults with anemia. Myelofibrosis is a disorder where normal bone marrow tissue is slowly substituted by fibrous, scar-like material. It is categorized as a form of chronic leukemia and...

Find More

Myelofibrosis Therapeutics Market 
Myelofibrosis Therapeutics Market

Myelofibrosis (MF) is a rare type of bone marrow cancer resulting in abnormal functioning of blood-forming cells and fibres. MF belongs to a group of disorders known as myeloproliferative disorders. This condition results in the widespread scarring of bone marrow leading to anaemia decreased count of platelets, and...

Find More